Effect Of Combined Therapy With Ekangavir Rasa-Vaitaran Basti-Shirobasti In Pakshavadh.

Phase 2

Conditions: Health Condition 1: G819- Hemiplegia, unspecifiedHealth Condition 2: G811- Spastic hemiplegiaHealth Condition 3: G811- Spastic hemiplegia

Registration Number: CTRI/2019/01/016872

Lead Sponsor: Govenment Ayurved College Nagpur

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Patients having signs and symptoms of hemiplegia i.e. Pakshavadh mentioned in Ayurvedic texts.

2.Patient having muscle power grade less or equal to 3

3.Patients of hemiplegia i.e. Pakshavadh due to cerebral thrombosis.

4.Patients of hemiplegia i.e. Pakshavadh of duration not more than 5 years.

5.Patients of either sex aged between 21 years -70 year.

6.Patient willing and able to participate in the study.

7.Patients who have not participated in any research project in last 6 months.

8.Patients of hemiplegia i.e. Pakshavadh having controlled hypertension (systolic upto140 mm of Hg and diastolic up to 90 mm of Hg) and diabetes mellitus (BSL fasting up to 130 mg/dl and Post Prandial up to 180 mg/dl).

Exclusion Criteria

1.Patients of cerebral infraction due to atrial fibrillation, embolic stroke, carotid occlusion, cerebellar stroke and haemorrhagic stroke will be excluded.

2.Patients having seizers, hydrocephalous, pulmonary embolism, dysphagia, M.I., cardiac arrhythmia and septicaemia will be excluded.

3.Patients who have lost bowel and bladder control.

4.Patients having acute progressive cerebral infarction

5.Comatose and unconscious patients.

6.Patients having age < 21 years and > 70 years will be excluded.

7.Patients having intra cranial infection, encephalitis and meningitis etc.

8.Patient having trauma, cerebral tumour, cerebral abscess.

9.Patient with congenital heart diseases like POA, ASD, VSD and FOD.

10.Patients contraindicated for Abhyanga like skin diseases, infective disease will be excluded.

11.Patients not fit for Basti.

12.Pregnant and lactating mothers.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To evaluate the effect of Ekangavir Rasa, Vaitarana Basti and Shirobasti in combination on Barthel Index and NIH Stroke Scale of Pakshavadh with special reference to Cerebral Infarction. <br/ ><br>2.To evaluate the effect of Ekangavir Rasa with Vaitarana Basti on Barthel Index and NIH Stroke score of Pakshavadh with special reference to Cerebral Infarction.Timepoint: 1) For trial Group Snehan Svedan with Til tail, Vaitarana Basti along with Shirobasti given for 16 days and Ekangavir Rasa 125 mg for 30 days <br/ ><br>2) For Control Group Snehan Svedan with Til tail, Vaitarana Basti given for 16 days and Ekangavir Rasa 125 mg for 30 days <br/ ><br>3) On day zero which will be termed as B.T. Value, second assessment will be done on 17th day and Final Assessment will be done on 31st day.

Secondary Outcome Measures